Old Web
English
Sign In
Acemap
>
authorDetail
>
Juan Shen
Juan Shen
Celgene
Fedratinib
Medicine
Ruxolitinib
Oncology
Internal medicine
2
Papers
28
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure.
2020
American Journal of Hematology
Claire N. Harrison
Nicolaas Schaap
Alessandro M. Vannucchi
Jean-Jacques Kiladjian
Eric Jourdan
Richard T. Silver
Harry C. Schouten
Francesco Passamonti
Sonja Zweegman
Moshe Talpaz
Srdan Verstovsek
Shelonitda Rose
Juan Shen
Tymara Berry
Carrie Brownstein
Ruben A. Mesa
Show All
Source
Cite
Save
Citations (26)
Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX
2019
Blood
Claire N. Harrison
Nicolaas Schaap
Alessandro M. Vannucchi
Jean-Jacques Kiladjian
Eric Jourdan
Richard T. Silver
Harry C. Schouten
Francesco Passamonti
Sonja Zweegman
Moshe Talpaz
Srdan Verstovsek
Shelonitda Rose
Juan Shen
Tymara Berry
Carrie Brownstein
Ruben A. Mesa
Show All
Source
Cite
Save
Citations (2)
1